Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico
| Autor: | Sergio Sandoval-Jiménez, Brenda Maldonado-Arriaga, Juan Antonio Suárez-Cuenca, Jonathan G. Shaw, Juan Rodríguez-Silverio, Sofía Lizeth Alcaráz Estrada, Cecilia Hernández-Cortez, Rebeca Pérez-Cabeza de Vaca, Tomás Cortés-Espinosa, Graciela Castro-Escarpulli, Paul Mondragón-Terán |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
viruses Disease Inflammatory bowel disease General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Feces Crohn's disease General Immunology and Microbiology business.industry virus diseases General Medicine biochemical phenomena metabolism and nutrition medicine.disease Ulcerative colitis digestive system diseases Biomarker (medicine) 030211 gastroenterology & hepatology Observational study Calprotectin business |
| Zdroj: | F1000Research. 9:1496 |
| ISSN: | 2046-1402 |
| Popis: | Background: Fecal calprotectin (FC) can be a valuable tool to optimize health care for patients with inflammatory bowel disease (IBD). The objective of this observational study was to determine the level of knowledge of the FC test in Mexican patients with IBD. Methods: A self-report questionnaire was distributed via Facebook to patients with IBD. The survey consisted of 15 questions in two categories: the first category assessed knowledge of IBD diagnosis, and the second category assessed knowledge of the FC test. Results: In total, 460 patients with IBD participated, of which 83.9% (386) had ulcerative colitis (UC) and 16.0% (74) had Crohn’s disease (CD). Regarding IBD diagnosis, 41.9% of participants stated that they did not know of a non-invasive test for fecal matter to identify inflammation of the colon. Regarding the FC test, 57.5% (UC) and 58.1% (CD) stated that they did not know about the test. Additionally, 65.8% (UC) and 51.3% (CD) of participants stated that they had never received the FC test and 82.6% (UC) and 77.0% (CD) recognized that the FC test was difficult to access in their medical practice. Furthermore, 66% (UC) and 52.7% (CD) of participants noted that their specialist doctor had never suggested the FC test to them, yet 89.1% (UC) and 87.8% (CD) stated that they would prefer FC analysis for their IBD follow-up assessments. Conclusions: There is little knowledge of the FC biomarker among Mexican patients with IBD. This suggests the need for greater dissemination of its use and scope as a biomarker in IBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|